Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-01-02
2007-01-02
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S054000, C514S221000, C514S970000, C514S973000, C536S103000
Reexamination Certificate
active
10827952
ABSTRACT:
A ras-farnesyltransferase inhibitor complex formed from a ras-farnesyltransferase inhibitor or a pharmaceutically acceptable salt thereof, a substituted cyclodextrin, and ethanol is provided. The complex has unexpectedly high aqueous solubility of the ras-farnesyltransferase inhibitor, improved dissolution, enhanced stability and is essentially free of particulate matter.
REFERENCES:
patent: 4371673 (1983-02-01), Pitha
patent: 4596795 (1986-06-01), Pitha
patent: 4727064 (1988-02-01), Pitha
patent: 5024998 (1991-06-01), Bodor
patent: 5134127 (1992-07-01), Stella et al.
patent: 5376645 (1994-12-01), Stella et al.
patent: 5602112 (1997-02-01), Rubinfeld
patent: 5646131 (1997-07-01), Badwan et al.
patent: 5804568 (1998-09-01), Rubinfeld
patent: 5855916 (1999-01-01), Chiesi et al.
patent: 6011029 (2000-01-01), Ding et al.
patent: 6048845 (2000-04-01), Rubinfeld
patent: 6218374 (2001-04-01), Rubinfeld
patent: 6218375 (2001-04-01), Raghavan et al.
patent: 6407079 (2002-06-01), Müller et al.
patent: 6455523 (2002-09-01), Ding et al.
patent: 1193197 (1970-05-01), None
patent: WO 95/06485 (1995-03-01), None
Saenger, “Cyclodextrin Inclusion Compounds in Research and Industry”, Angew. Chem. Int. Ed. Engl., 19, pp. 344-362 (1980).
Okimoto et al., Pharmaceutical Research, 13, pp. 256-264 (1996).
Tinwalla et al., Pharmaceutical Research, 10, pp. 1136-1143 (1993).
Szejtli, “Cyclodextrins in Drug Formulations: Part I”, Pharmaceutical Technology, pp. 36-44, Jun. 1991.
Rajewski et al., Journal of Pharmaceutical Sciences, 85 (11), pp. 1142-1168 (1996).
Chemical Abstracts 127:278213, “Imidazole-containing benzodiazepines and analogs as inhibitors of farnesyl protein transferase”.
Brewster et al., “Effect of various cyclodextrins on solution stability and dissolution rate of doxorubicin hydrochloride”, International Journal of Pharmaceutics, vol. 79, pp. 289-299 (1992).
Fenyvesi et al., “Water-Soluble Cyclodextrin Polymers and Their Complexing Properties,” First International Symposium of Cyclodextrins, Budapest, Hungary 1981. J. Szejti, Editor. D. Reidel Publishing Co., 1982. pp. 345-359.
Pitha, Josef et al., “Effects of ethanol on formation of inclusion complexes of hydroxypropylcyclodextrins with testosterone or with methyl orange”, Int'l J. of Pharmaceutics, 80, pp. 243-251 (1992).
Reer, Olaf et al., “Investigation of the Influence of Cosolvents and Surfactants on the Complexation of Dexamethasone with Hydroxypropyl-β-Cyclodextrin by Use of a Simple Lattice design”, Eur. J. Pharm. Biopharm., 39 (3), pp. 105-111 (1993).
“Data Sheet: Hydroxypropyl B Cyclodextrin, Endotoxin Controlled”, at http://www.researchd.com/janssen/410200.htm, pp. 1-13 (last visited Aug. 4, 2005).
Cucolo Michael
Nassar Munir N.
Smith Anne Marie
Bristol Myers Squibb Company
Cohen Jacqueline M.
Gibbons Maureen
Henry Michael C.
Jiang Shaojia Anna
LandOfFree
Complex of ras-farnesyltransferase inhibitor, a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Complex of ras-farnesyltransferase inhibitor, a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Complex of ras-farnesyltransferase inhibitor, a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3751038